title: Inhibition of platelet function by abciximab or high-dose tirofiban in patients with STEMI undergoing primary PCI: a randomised trial.
abstract: BACKGROUND
  In patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary PCI, few data exist on the magnitude of platelet activation, aggregation and dosing of glycoprotein (GP) IIb/IIIa receptor inhibitors.
  
  
  METHODS
  Sixty STEMI patients were randomised to abciximab, to high-dose tirofiban or to no additional GP IIb/IIIa inhibitor treatment. Platelet activation (P-selectin expression) was measured using flow cytometry and the level of inhibition of platelet aggregation was assessed using the Plateletworks assay. Additionally, the PFA-100 with the collagen/adenosine-diphosphate cartridge (CADP) was used to compare the levels of platelet inhibition. All measurements were performed at baseline (T(0)), immediately after (T(1)), 30 minutes (T(2)), 60 minutes (T(3)) and 120 minutes (T(4)) after primary PCI.
  
  
  RESULTS
  The level of platelet activation in both GP IIb/IIIa receptor inhibitor treated groups was significantly lower compared with the control group at all time points after primary PCI (p=0.04). Also the administration of the currently recommended dose of abciximab resulted in significantly lower levels of inhibition of aggregation compared with high-dose tirofiban (p<0.0001). In addition, the CADP closure times were significantly prolonged in both GP IIb/IIIa inhibitor treated groups compared with the control group at time points T(1) (p=0.006) and T(4) (p<0.0001).
  
  
  CONCLUSIONS
  The administration of high-dose tirofiban resulted in a significantly higher inhibition of platelet aggregation compared with the currently recommended dose of abciximab. Large clinical trials are needed to assess whether this laboratory superiority of high-dose tirofiban translates into higher clinical efficacy. (Neth Heart J 2007;15:375-81.).
authors.affiliation: Department of Cardiology, St Antonius Hospital, Nieuwegein, the Netherlands.
authors.forename: J W
authors.initials: JW
authors.lastname: van Werkum
authors.forename: W B M
authors.initials: WB
authors.lastname: Gerritsen
authors.forename: J C
authors.initials: JC
authors.lastname: Kelder
authors.forename: C M
authors.initials: CM
authors.lastname: Hackeng
authors.forename: S M
authors.initials: SM
authors.lastname: Ernst
authors.forename: V H M
authors.initials: VH
authors.lastname: Deneer
authors.forename: M J
authors.initials: MJ
authors.lastname: Suttorp
authors.forename: B J W M
authors.initials: BJ
authors.lastname: Rensing
authors.forename: H W M
authors.initials: HW
authors.lastname: Plokker
authors.forename: J M
authors.initials: JM
authors.lastname: Ten Berg